TCM-based new drug discovery and development in China.
10.1016/S1875-5364(14)60050-9
- Author:
Wan-Ying WU
1
;
Jin-Jun HOU
1
;
Hua-Li LONG
1
;
Wen-Zhi YANG
1
;
Jian LIANG
1
;
De-An GUO
2
Author Information
1. Shanghai Research Center for Modernization of Traditional Chinese Medicine and National Engineering Laboratory for TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
2. Shanghai Research Center for Modernization of Traditional Chinese Medicine and National Engineering Laboratory for TCM Standardization Technology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China. Electronic address: daguo@simm.ac.cn.
- Publication Type:Journal Article
- Keywords:
China;
China Food and Drug Administration (CFDA);
Drug development;
Drug discovery;
Regulatory classification;
Traditional Chinese Medicine
- MeSH:
China;
Drug Discovery;
legislation & jurisprudence;
standards;
Drugs, Chinese Herbal;
analysis;
standards;
Medicine, Chinese Traditional;
standards
- From:
Chinese Journal of Natural Medicines (English Ed.)
2014;12(4):241-250
- CountryChina
- Language:English
-
Abstract:
Over the past 30 years, China has significantly improved the drug development environment by establishing a series of policies for the regulation of new drug approval. The regulatory system for new drug evaluation and registration in China was gradually developed in accordance with international standards. The approval and registration of TCM in China became as strict as those of chemical drugs and biological products. In this review, TCM-based new drug discovery and development are introduced according to the TCM classification of nine categories.
